TY - JOUR
T1 - Clinical outcomes after surgery for primary aldosteronism
T2 - Evaluation of the PASO-investigators' consensus criteria within a worldwide cohort of patients
AU - Vorselaars, Wessel M. C. M.
AU - van Beek, Dirk-Jan
AU - Postma, Emily L.
AU - Spiering, Wilko
AU - Rinkes, Inne H. M. Borel
AU - Valk, Gerlof D.
AU - Vriens, Menno R.
AU - Zarnegar, Rasa
AU - Drake, Frederick T.
AU - Duh, Quan Y.
AU - Talutis, Stephanie D.
AU - McAneny, David B.
AU - McManus, Catherine
AU - Lee, James A.
AU - Grant, Scott B.
AU - Grogan, Raymon H.
AU - Arenas, Minerva A. Romero
AU - Perrier, Nancy D.
AU - Peipert, Benjamin J.
AU - Mongelli, Michael N.
AU - Castelino, Tanya
AU - Mitmaker, Elliot J.
AU - Parente, David N.
AU - Pasternak, Jesse D.
AU - Engelsman, Anton E.
AU - Sywak, Mark
AU - D'Amato, Gerardo
AU - Raffaelli, Marco
AU - Schuermans, Valerie
AU - Bouvy, Nicole D.
AU - Eker, Hasan H.
AU - Bonjer, H. Jaap
AU - Morel, Nina M. Vaarzon
AU - van Dijkum, Els J. M. Nieveen
AU - Metman, Madelon J. H.
AU - Kruijff, Schelto
AU - International CONNsortium study group
N1 - Funding Information:
Rasa Zarnegar, MD,d Frederick T. Drake, MD,e,f Quan Y. Duh, MD,e Stephanie D. Talutis, MD,f David B. McAneny, MD,f Catherine McManus, MD,g James A. Lee, MD,g Scott B. Grant, MD,h Raymon H. Grogan, MD,i Minerva A. Romero Arenas, MD, MPH,j Nancy D. Perrier, MD,j Benjamin J. Peipert, BA,k Michael N. Mongelli, BS,k Tanya Castelino, MD,l Elliot J. Mitmaker, MD,j David N. Parente, MD,l Jesse D. Pasternak, MD,m Anton F. Engelsman, MD,n Mark Sywak, MD,n Gerardo D'Amato, MD,o Marco Raffaelli, MD,o Valerie Schuermans, MD,p Nicole D. Bouvy, MD,p Hasan H. Eker, MD,q H. Jaap Bonjer, MD,q Nina M. Vaarzon Morel, BA,r Els J.M. Nieveen van Dijkum, MD,r Madelon J.H. Metman, MD,s and Schelto Kruijff, MDs
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/7
Y1 - 2019/7
N2 - Background: In a first step toward standardization, the Primary Aldosteronism Surgical Outcomes investigators introduced consensus criteria defining the clinical outcomes after adrenalectomy for primary aldosteronism. Within this retrospective cohort study, we evaluated the use of these consensus criteria in daily clinical practice in 16 centers in Europe, Canada, Australia, and the United States.Methods: Patients who underwent unilateral adrenalectomy for primary aldosteronism between 2010 and 2016 were included. Patients with missing data regarding preoperative or postoperative blood pressure or their defined daily dose were excluded. According to the Primary Aldosteronism Surgical Outcomes criteria, patients were classified as complete, partial, or absent clinical success.Results: A total of 380 patients were eligible for analysis. Complete, partial, and absent clinical success was achieved in 30%, 48%, and 22%, respectively. Evaluation of the Primary Aldosteronism Surgical Outcomes criteria showed that in 11% and 47% of patients with partial and absent clinical success, this classification was incorrect or debatable (16% of the total cohort). This concept of a "debatable classification of success" was due mainly to the cutoff of >= 20 mmHg used to indicate a clinically relevant change in systolic blood pressure and the use of percentages instead of absolute values to indicate a change in defined daily dose.Conclusion: Although introduction of the Primary Aldosteronism Surgical Outcomes consensus criteria induced substantial advancement in the standardization of postoperative outcomes, our study suggests that there is room for improvement in the concept for success given the observed limitations when the criteria were tested within our international cohort. In line, determining clinical success remains challenging, especially in patients with opposing change in blood pressure and defined daily dose. (C) 2019 Elsevier Inc. All rights reserved.
AB - Background: In a first step toward standardization, the Primary Aldosteronism Surgical Outcomes investigators introduced consensus criteria defining the clinical outcomes after adrenalectomy for primary aldosteronism. Within this retrospective cohort study, we evaluated the use of these consensus criteria in daily clinical practice in 16 centers in Europe, Canada, Australia, and the United States.Methods: Patients who underwent unilateral adrenalectomy for primary aldosteronism between 2010 and 2016 were included. Patients with missing data regarding preoperative or postoperative blood pressure or their defined daily dose were excluded. According to the Primary Aldosteronism Surgical Outcomes criteria, patients were classified as complete, partial, or absent clinical success.Results: A total of 380 patients were eligible for analysis. Complete, partial, and absent clinical success was achieved in 30%, 48%, and 22%, respectively. Evaluation of the Primary Aldosteronism Surgical Outcomes criteria showed that in 11% and 47% of patients with partial and absent clinical success, this classification was incorrect or debatable (16% of the total cohort). This concept of a "debatable classification of success" was due mainly to the cutoff of >= 20 mmHg used to indicate a clinically relevant change in systolic blood pressure and the use of percentages instead of absolute values to indicate a change in defined daily dose.Conclusion: Although introduction of the Primary Aldosteronism Surgical Outcomes consensus criteria induced substantial advancement in the standardization of postoperative outcomes, our study suggests that there is room for improvement in the concept for success given the observed limitations when the criteria were tested within our international cohort. In line, determining clinical success remains challenging, especially in patients with opposing change in blood pressure and defined daily dose. (C) 2019 Elsevier Inc. All rights reserved.
KW - ADRENALECTOMY
KW - CARDIOVASCULAR-DISEASE
KW - EVENTS
KW - HYPERALDOSTERONISM
KW - HYPERTENSION CURE
KW - PRESSURE-LOWERING DRUGS
KW - PREVALENCE
KW - RESOLUTION SCORE
KW - UNILATERAL PRIMARY ALDOSTERONISM
KW - MANAGEMENT
U2 - 10.1016/j.surg.2019.01.031
DO - 10.1016/j.surg.2019.01.031
M3 - Article
C2 - 31053245
SN - 0039-6060
VL - 166
SP - 61
EP - 68
JO - Surgery
JF - Surgery
IS - 1
ER -